ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BR3409

A development code.

Its studies are mostly in Diabetes Mellitus, Type 2, led by Boryung Pharmaceutical.

Furthest: phase 1, since Mar 11, 20252 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boryung Pharmaceutical20 open or runningphase 1since Mar 11, 2025Mar 11, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2025First studies: 2 phase 1 studies in Diabetes Mellitus, Type 2First studyNCT06879158, NCT06879132

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06879158Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedJan 26, 202550
NCT06879132Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedDec 7, 202440

How it is read

Names in the registry

  • “BR3409”, 2 entries

Codes read as this program: BR3409.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.